Rheumatoid Arthritis Therapy Reappraisal : Strategies, Opportunities and Challenges
Rheumatoid Arthritis (RA) is a chronic inflammatory disease leading to joint inflammation and destruction. Treatment of RA includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs), and oral or intraarticular (IA) glucocorticoids (GCs). All different classes...
Saved in:
Sonstige: | |
---|---|
Year of Publication: | 2020 |
Language: | English |
Physical Description: | 1 electronic resource (260 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993545813504498 |
---|---|
ctrlnum |
(CKB)5400000000041175 (oapen)https://directory.doabooks.org/handle/20.500.12854/69097 (EXLCZ)995400000000041175 |
collection |
bib_alma |
record_format |
marc |
spelling |
Müller, Rüdiger edt Rheumatoid Arthritis Therapy Reappraisal Strategies, Opportunities and Challenges Rheumatoid Arthritis Therapy Reappraisal Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020 1 electronic resource (260 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Rheumatoid Arthritis (RA) is a chronic inflammatory disease leading to joint inflammation and destruction. Treatment of RA includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs), and oral or intraarticular (IA) glucocorticoids (GCs). All different classes of drugs have shown to halt disease progression in clinical studies. In real life, a physician has more options than just adding or switching to a new ts/bDMARD if any kind of DMARDs has failed. They can modify or optimize the therapy with concomitant csDMARDs, and oral or IA-GC can be added to the treatment regimen. The EULAR states that therapeutic adjustment including the "optimization of csDMARDs dose or route of administration or intra-articular injections of GCs" is recommended. Thus, a new therapeutic agent can be embedded in a whole strategy with parallel optimization of the csDMARD and GC treatment. The idea of treating to target (T2T) for the treatment of RA patients has been around since the late 1990s. Many clinical studies (Ticora, BsSt, Camera) have demonstrated the superiority of a T2T approach. When I talk to physicians, I understand that most of them only rarely inject joints with GC. Therefore, I would like to create an issue on the T2T approach in reality including primary data, reviews, and real-life data demonstrating the general opinion and execution of T2T in treating RA. English Medicine bicssc rheumatoid arthritis sleep sleep disorders pain osteoporosis fracture fracture risk assessment tool treat-to-target certolizumab pegol csDMARDs glucocorticoids intra-articular injections DAS 28 ACR response HAQ-DI TNFα golimumab efficacy tolerability immunogenicity methotrexate posology titration oral route subcutaneous route bioavailability effectiveness periodontitis periodontal disease anti-citrullinated protein autoantibodies rheumatoid factor smoking medication Porphyromonas gingivalis Rheumatoid arthritis matrix metalloproteinase 3 infliximab pharmacogenomics anti-TNF personalized medicine baricitinib disease-modifying antirheumatic drugs pain perception outcomes research patient perspective Rheumatoid Arthritis therapy DMARD MTX Tumor Necrosis Factor-Alpha Inhibitors ankylosing spondylitis biosimilar switching synovial fibroblasts cytokine osteoclast herbal medicine methylation next-generation sequencing recovery of function fatigue productivity tofacitinib oral Th1.17 IL-17A IFN-γ, CD73 adenosine psoriatic arthritis regulation pseudoerosions hand foot ultrasonography radiography computed tomography magnetic resonance imaging 3-03943-090-4 3-03943-091-2 Müller, Rüdiger oth |
language |
English |
format |
eBook |
author2 |
Müller, Rüdiger |
author_facet |
Müller, Rüdiger |
author2_variant |
r m rm |
author2_role |
Sonstige |
title |
Rheumatoid Arthritis Therapy Reappraisal Strategies, Opportunities and Challenges |
spellingShingle |
Rheumatoid Arthritis Therapy Reappraisal Strategies, Opportunities and Challenges |
title_sub |
Strategies, Opportunities and Challenges |
title_full |
Rheumatoid Arthritis Therapy Reappraisal Strategies, Opportunities and Challenges |
title_fullStr |
Rheumatoid Arthritis Therapy Reappraisal Strategies, Opportunities and Challenges |
title_full_unstemmed |
Rheumatoid Arthritis Therapy Reappraisal Strategies, Opportunities and Challenges |
title_auth |
Rheumatoid Arthritis Therapy Reappraisal Strategies, Opportunities and Challenges |
title_alt |
Rheumatoid Arthritis Therapy Reappraisal |
title_new |
Rheumatoid Arthritis Therapy Reappraisal |
title_sort |
rheumatoid arthritis therapy reappraisal strategies, opportunities and challenges |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2020 |
physical |
1 electronic resource (260 p.) |
isbn |
3-03943-090-4 3-03943-091-2 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT mullerrudiger rheumatoidarthritistherapyreappraisalstrategiesopportunitiesandchallenges AT mullerrudiger rheumatoidarthritistherapyreappraisal |
status_str |
n |
ids_txt_mv |
(CKB)5400000000041175 (oapen)https://directory.doabooks.org/handle/20.500.12854/69097 (EXLCZ)995400000000041175 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Rheumatoid Arthritis Therapy Reappraisal Strategies, Opportunities and Challenges |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1787548708704878592 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04829nam-a2201225z--4500</leader><controlfield tag="001">993545813504498</controlfield><controlfield tag="005">20231214133314.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000041175</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/69097</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000041175</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Müller, Rüdiger</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Rheumatoid Arthritis Therapy Reappraisal</subfield><subfield code="b">Strategies, Opportunities and Challenges</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Rheumatoid Arthritis Therapy Reappraisal </subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (260 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Rheumatoid Arthritis (RA) is a chronic inflammatory disease leading to joint inflammation and destruction. Treatment of RA includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs), and oral or intraarticular (IA) glucocorticoids (GCs). All different classes of drugs have shown to halt disease progression in clinical studies. In real life, a physician has more options than just adding or switching to a new ts/bDMARD if any kind of DMARDs has failed. They can modify or optimize the therapy with concomitant csDMARDs, and oral or IA-GC can be added to the treatment regimen. The EULAR states that therapeutic adjustment including the "optimization of csDMARDs dose or route of administration or intra-articular injections of GCs" is recommended. Thus, a new therapeutic agent can be embedded in a whole strategy with parallel optimization of the csDMARD and GC treatment. The idea of treating to target (T2T) for the treatment of RA patients has been around since the late 1990s. Many clinical studies (Ticora, BsSt, Camera) have demonstrated the superiority of a T2T approach. When I talk to physicians, I understand that most of them only rarely inject joints with GC. Therefore, I would like to create an issue on the T2T approach in reality including primary data, reviews, and real-life data demonstrating the general opinion and execution of T2T in treating RA.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">rheumatoid arthritis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sleep</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sleep disorders</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pain</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">osteoporosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fracture</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fracture risk assessment tool</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treat-to-target</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">certolizumab pegol</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">csDMARDs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glucocorticoids</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">intra-articular injections</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DAS 28</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ACR response</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HAQ-DI</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TNFα</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">golimumab</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">efficacy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tolerability</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunogenicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">methotrexate</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">posology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">titration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oral route</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">subcutaneous route</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bioavailability</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">effectiveness</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">periodontitis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">periodontal disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-citrullinated protein autoantibodies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">rheumatoid factor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">smoking</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">medication</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Porphyromonas gingivalis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Rheumatoid arthritis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">matrix metalloproteinase 3</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">infliximab</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pharmacogenomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-TNF</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">personalized medicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">baricitinib</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">disease-modifying antirheumatic drugs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pain perception</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">outcomes research</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">patient perspective</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Rheumatoid Arthritis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DMARD</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MTX</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Tumor Necrosis Factor-Alpha Inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ankylosing spondylitis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biosimilar</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">switching</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">synovial fibroblasts</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytokine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">osteoclast</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">herbal medicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">methylation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">next-generation sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">recovery of function</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fatigue</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">productivity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tofacitinib</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oral</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Th1.17</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">IL-17A</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">IFN-γ, CD73</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adenosine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">psoriatic arthritis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">regulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pseudoerosions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hand</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">foot</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ultrasonography</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radiography</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">computed tomography</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">magnetic resonance imaging</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-090-4</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-091-2</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Müller, Rüdiger</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:49:52 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338026590004498&Force_direct=true</subfield><subfield code="Z">5338026590004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338026590004498</subfield></datafield></record></collection> |